Targeting the IL-12/IL-23 axis: An alternative approach to removing tumor induced immune suppression

Combination immune checkpoint blockade has demonstrated significant clinical responses in cancers infiltrated by T cells. Many tumors contain high proportions of myeloid cells and these can secrete immunosuppressive cytokines like IL-23. Our data suggest the clinical potential of using anti-CD40 (pu...

Descripción completa

Detalles Bibliográficos
Autores principales: Smyth, Mark J, Teng, Michele W L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2014
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4108456/
https://www.ncbi.nlm.nih.gov/pubmed/25083324
http://dx.doi.org/10.4161/onci.28964
_version_ 1782327761017241600
author Smyth, Mark J
Teng, Michele W L
author_facet Smyth, Mark J
Teng, Michele W L
author_sort Smyth, Mark J
collection PubMed
description Combination immune checkpoint blockade has demonstrated significant clinical responses in cancers infiltrated by T cells. Many tumors contain high proportions of myeloid cells and these can secrete immunosuppressive cytokines like IL-23. Our data suggest the clinical potential of using anti-CD40 (push) and anti-IL-23 mAbs (pull) to tip the IL-12/23 balance in established tumors and act as an alternative combination cancer immunotherapy.
format Online
Article
Text
id pubmed-4108456
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Landes Bioscience
record_format MEDLINE/PubMed
spelling pubmed-41084562014-07-31 Targeting the IL-12/IL-23 axis: An alternative approach to removing tumor induced immune suppression Smyth, Mark J Teng, Michele W L Oncoimmunology Author's View Combination immune checkpoint blockade has demonstrated significant clinical responses in cancers infiltrated by T cells. Many tumors contain high proportions of myeloid cells and these can secrete immunosuppressive cytokines like IL-23. Our data suggest the clinical potential of using anti-CD40 (push) and anti-IL-23 mAbs (pull) to tip the IL-12/23 balance in established tumors and act as an alternative combination cancer immunotherapy. Landes Bioscience 2014-05-23 /pmc/articles/PMC4108456/ /pubmed/25083324 http://dx.doi.org/10.4161/onci.28964 Text en Copyright © 2014 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Author's View
Smyth, Mark J
Teng, Michele W L
Targeting the IL-12/IL-23 axis: An alternative approach to removing tumor induced immune suppression
title Targeting the IL-12/IL-23 axis: An alternative approach to removing tumor induced immune suppression
title_full Targeting the IL-12/IL-23 axis: An alternative approach to removing tumor induced immune suppression
title_fullStr Targeting the IL-12/IL-23 axis: An alternative approach to removing tumor induced immune suppression
title_full_unstemmed Targeting the IL-12/IL-23 axis: An alternative approach to removing tumor induced immune suppression
title_short Targeting the IL-12/IL-23 axis: An alternative approach to removing tumor induced immune suppression
title_sort targeting the il-12/il-23 axis: an alternative approach to removing tumor induced immune suppression
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4108456/
https://www.ncbi.nlm.nih.gov/pubmed/25083324
http://dx.doi.org/10.4161/onci.28964
work_keys_str_mv AT smythmarkj targetingtheil12il23axisanalternativeapproachtoremovingtumorinducedimmunesuppression
AT tengmichelewl targetingtheil12il23axisanalternativeapproachtoremovingtumorinducedimmunesuppression

Ejemplares similares